References
- Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075.
- Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. IQVIA 2019 Report. [cited 2022 Jan 10]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023.
- Brill A, Ippolito B. The economics of biologic drugs: a further response to Bach et al. [cited 2022 Jan 10].
- Biological Product Definitions. U.S. Food and Drug Administration. [cited 2022 Jan 10]. Available from: https://www.fda.gov/files/drugs/published/Biological-Product-Definitions.pdf.
- Blackstone EA, Fuhr JP. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–478.
- Kabir ER, Moreino SS, Sharif Siam MK. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9(9):410.
- FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira. U.S. Food and Drug Administration. [cited 2022 Jan 10]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-cyltezo-first-interchangeable-biosimilar-humira.
- Biosimilars gain widespread adoption by health plans. [cited 2022 Jan 10]. Available from: https://Avalere.com/press-releases/biosimilars-gain-widespread-adoption-by-health-plans.
- Socal MP, Bai G, Anderson GF. Favorable formulary placement of branded drugs in Medicare prescription drug plans when generics are available. JAMA Intern Med. 2019;179(6):832–833.
- Ventola CL. Evaluation of biosimilars for formulary inclusion: factors for consideration by P&T committees. P T. 2015;40(10):680–689.
- Biosimilar product information. FDA-approved biosimilar products. U.S. Food and Drug Administration. [cited 2022 Jan 10]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information.
- Top 4 Biosimilar Developments of 2021. [cited 2022 Jan 14]. Available from: https://www.managedhealthcareexecutive.com/view/top-4-biosimilar-developments-of-2021.
- Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum. 2008;58(1):15–25.
- Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471.
- Targeted immune modulators for rheumatoid arthritis: Effectiveness & value. Institute for Clinical and Economic Review. [cited 2022 Jan 10]. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_RA_Final_Scoping_Document_050919.pdf.
- The impact of biosimilar competition in Europe. October 2019. IQVIA. [cited 2022 Jan 10]. Available from: https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe.
- Inflectra® (infliximab-dyyb) Prescribing Information. [cited 2022 Jan 10]. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=9271.
- Renflexis (infliximab-abda) Prescribing Information. [cited 2022 Jan 10]. Available from: https://www.organon.com/product/usa/pi_circulars/r/renflexis/renflexis-pi.pdf.
- Truxima (rituximab-abbs) Prescribing Information. [cited 2022 May 5]. Available from: https://www.truxima.com/globalassets/truxima-dtc/pdfs/truxima-prescribing-information.pdf.
- Ruxience (rituximab-pvvr) Prescribing Information. [cited 2022 May 5]. Available from: https://labeling.pfizer.com/ShowLabeling.aspx?id=12090.
- Riabni (rituximab-arrx) Prescribing Information. [cited 2022 July 23]. Available from: https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Riabni/riabni_pi_english.pdf.
- Bhattacharya J, Vogt WB. A simple model of pharmaceutical price dynamics. J Law Econ. 2003;46(2):599–626.
- Vondeling GT, Cao Q, Postma MJ, et al. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16(5):653–660.
- Reynolds A, Koenig AS, Bananis E, et al. When is switching warranted among biologic therapies in rheumatoid arthritis? Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):319–333.
- Dolinar R, Kohn CG, Lavernia F, et al. The non-medical switching of prescription medications. Postgrad Med. 2019;131(5):335–341.
- Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018;9:1070.
- Singh JA, Saag KG, Bridges SL, Jr, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
- Enabling competition in pharmaceutical markets. [cited 2022 Jan 10]. Available from: https://www.brookings.edu/research/enabling-competition-in-pharmaceutical-markets/.
- Miller S, Houts J. Potential savings of biogenerics in the United States. St Louis: Express Scripts; 2007. [cited 2022 Jan 10]. Available from: https://www.proquest.com/docview/207119687.
- Congressional Budget Office Cost estimate: S. 1695 Biologics Price Competition and Innovation Act of 2007. [cited 2022 Jan 10]. Available from: https://www.cbo.gov/sites/default/files/110th-congress-2007-2008/costestimate/s16950.pdf.
- National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Ensuring Patient Access to Affordable Drug Therapies; Nass SJ, Madhavan G, Augustine NR, editors. Making Medicines Affordable: A National Imperative. Washington (DC): National Academies Press (US); 2017. [cited 2017 Nov 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493094/.
- Chandra A, Vanderpuye-Orgle J. Competition in the age of biosimilars. JAMA. 2015;314(3):225–226.
- Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev Drug Discov. 2014;13(2):99–100.
- Hung A, Vu Q, Mostovoy L. A systematic review of US biosimilar approvals: what evidence does the FDA require and how are manufacturers responding? J Manag Care Spec Pharm. 2017;23(12):1234–1244.
- Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in Central and Eastern European countries. Front Pharmacol. 2017;8:288.
- Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov. 2008;7(9):733–737.
- Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
- Mulcahy AW, Predmore Z, Mattke S. The cost savings potential of biosimilar drugs in the United States. Santa Monica, CA: RAND Corporation, PE-127-SANI, 2014.
- Nabhan C, Parsad S, Mato AR, et al. Biosimilars in oncology in the United States: a review. JAMA Oncol. 2018;4(2):241–247.
- Sussell J, Vanderpuye-Orgle J, Vania D, et al. Understanding price growth in the market for targeted oncology therapies. Am J Manag Care. 2019;25(6):273–277.
- Rocco P, Eberini I, Musazzi UM, et al. Glatiramer acetate: a complex drug beyond biologics. Eur J Pharm Sci. 2019;133:8–14.
- Biomedtracker. Informa Pharma Intelligence. [cited 2022 Jan 10]. Available from: https://www.biomedtracker.com/.
- AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023. [cited 2022 Jan 10]. Available from: https://www.reuters.com/article/us-abbvie-amgen-humira-idUSKCN1C32G5.
- Suda KJ, Halbur DJ, Hunkler RJ, et al. Spending on hepatitis C antivirals in the United States, 2009–2015. Pharmacotherapy. 2017;37(1):65–70.
- Yarbrough CR. How protected classes in Medicare part D influence U.S. drug sales, utilization, and price. Health Econ. 2020;29(5):608–623.
- Grabowski H, Long G, Mortimer R. Recent trends in Brand-name and generic drug competition. J Med Econ. 2014;17(3):207–214.
- Grabowski H, Long G, Mortimer R, et al. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836–844.
- Hemphill CS, Sampat BN. Evergreening, patent challenges, and effective market life in pharmaceuticals. J Health Econ. 2012;31(2):327–339.
- HUMIRA (adalimumab) Injection. Prescribing information. North Chicago, IL: AbbVie Inc.
- Cessak G, Kuzawińska O, Burda A, et al. TNF inhibitors–mechanisms of action, approved and off-label indications. Pharmacol Rep. 2014;66(5):836–844.
- Gerriets V, Bansal P, Goyal A, et al. Tumor necrosis factor inhibitors. In StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
- Snider JT, Sussell J, Tebeka MG, et al. Challenges with forecasting budget impact: a case study of six icer reports. Value Health. 2019;22(3):332–339.
- Imbens GW, Lemieux T. Regression discontinuity designs: a guide to practice. J Econom. 2008;142(2):615–635.
- Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit. 2010;48(2):281–355.
- Thistlethwaite DL, Campbell DT. Regression-discontinuity analysis: an alternative to the ex post facto experiment. J Educ Psychol. 1960;51(6):309–317.
- Kolesár M, Rothe C. Inference in regression discontinuity designs with a discrete running variable. Am Econ Rev. 2018;108(8):2277–2304.
- Calonico S, Cattaneo MD, Farrell MH. On the effect of bias estimation on coverage accuracy in nonparametric inference. J Am Stat Assoc. 2018;113(522):767–779.
- Calonico S, Cattaneo MD, Farrell MH, et al. Rdrobust: software for regression-discontinuity designs. Stata J. 2017;17(2):372–404.
- Congressional Budget Office. Processes. [cited 2022 Jan 10]. Available from: https://www.cbo.gov/about/processes#methodology.
- National Health Expenditure Data. Spillovers in health care markets: implications for current law projections; Dec 10, 2022.
- Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533–544.
- Castanheira M, Ornaghi C, Siotis G. The unexpected consequences of generic entry. J Health Econ. 2019;68:102243.
- Dusetzina SB, Cubanski J, Nshuti L, et al. Medicare part D plans rarely cover brand-name drugs when generics are available: study examines Medicare part D coverage to quantify how often brand-name drugs are designated preferred over generics. Health Aff. 2020;39(8):1326–1333.